Imaging agents and methods of use

US10953113B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10953113-B2
Application numberUS-201716465887-A
CountryUS
Kind codeB2
Filing dateNov 30, 2017
Priority dateDec 2, 2016
Publication dateMar 23, 2021
Grant dateMar 23, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[18F]fluoroglucaric acid (18F-FGA), or a pharmaceutically-acceptable salt thereof. The imaging agent may be disposed in a pharmaceutically-acceptable excipient, carrier, diluent, or vehicle. The imaging agent may be contained within a kit. The disclosure includes in at least one embodiment a method of preparing a radiopharmaceutical such as 18F-FGA for use in imaging.

First claim

Opening claim text (preview).

What is claimed is: 1. A process for preparing a radiopharmaceutical composition, comprising: combining a quantity of 2-deoxy-2-[ 18 F]fluoro-D-glucose ( 18 F-FDG) with an oxidizing agent, a reaction accelerator, and an alkaline buffering agent to form a first mixture; adding a reaction initiator to the first mixture to form a reaction mixture; and incubating the reaction mixture, wherein substantially all of the 18 F-FDG is converted into 2-deoxy-2-[ 18 F]fluoroglucaric acid ( 18 F-FGA) in less than about 10 minutes after adding the reaction initiator, and wherein the conversion of 18 F-FDG into 18 F-FGA occurs without monitoring and adjusting the pH of the reaction mixture, thereby preparing the radiopharmaceutical composition and, after conversion of the 18 F-FDG into 18 F-FGA, adding an acid to the reaction mixture to change the pH of the reaction mixture to a pH in a range of about 6.5 to about 7.5. 2. The process of claim 1 , wherein the oxidizing agent is selected from the group consisting of 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO), 4-hydroxy-TEMPO, TEMPO methacrylate, 4-oxo-TEMPO, 4-amino-TEMPO, 4-acetamido-TEMPO, 4-carboxy-TEMPO, 4-hydroxy-TEMPO benzoate, 4-(2-iodoacetamido)-TEMPO, 4-maleimido-TEMPO, 4-isothiocyanato-TEMPO, 4-(2-bromoacetamido)-TEMPO, 4-methoxy-TEMPO, 4-cyano-TEMPO, 4-amino-4-carboxy-TEMPO, 4-phosphonooxy-TEMPO hydrate, 2,2,6,6-tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, hydrogen peroxide, sodium hypochlorite, calcium hypochlorite, ozone, nitric acid, permanganate compounds, halogens, metal-catalyzed oxidation agents, gold nanoparticles, nanoparticles which mimic peroxidase activity-mimicking nanoparticles, glucose oxidase, and glucose-oxidizing enzymes or compounds. 3. The process of claim 1 , wherein the alkaline buffering agent has a buffering capacity in a pH range of about 9 to about 12. 4. The process of claim 1 , wherein the incubating step occurs at a reaction temperature in a range of about 0° C. to about 25° C. 5. The process of claim 1 , wherein the oxidizing agent is a free compound, or is linked to a bead, resin, or polymer. 6. The process of claim 1 , wherein the reaction initiator is selected from the group consisting of sodium hypochlorite and calcium hypochlorite and the reaction accelerator is selected from the group consisting of sodium bromide and potassium bromide. 7. The process of claim 1 , wherein the alkaline buffering agent is a bicarbonate buffer. 8. The process of claim 7 , wherein the bicarbonate buffer is sodium bicarbonate.

Assignees

Inventors

Classifications

  • containing halogen · CPC title

  • Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids · CPC title

  • Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers · CPC title

  • Processes for the preparation of sugar derivatives · CPC title

  • with halogen-containing compounds which may be formed in situ · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10953113B2 cover?
An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[18F]fluoroglucaric acid (18F-FGA), or a pharmaceutically-acceptable salt thereof. The imaging agent may be disposed in a pharmaceutically-acceptable excipient, carrier, diluent, o…
Who is the assignee on this patent?
Univ Oklahoma
What technology area does this patent fall under?
Primary CPC classification A61K51/0491. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).